Compare PVLA & TMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PVLA | TMC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2013 | 2020 |
| Metric | PVLA | TMC |
|---|---|---|
| Price | $150.33 | $5.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $171.87 | $8.85 |
| AVG Volume (30 Days) | 154.3K | ★ 6.4M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 52.62 | ★ 232.00 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $42,810,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104,350.18 | N/A |
| P/E Ratio | ★ N/A | $26.07 |
| Revenue Growth | ★ 65.28 | N/A |
| 52 Week Low | $49.81 | $3.40 |
| 52 Week High | $161.38 | $11.35 |
| Indicator | PVLA | TMC |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 66.58 |
| Support Level | $109.68 | $4.81 |
| Resistance Level | $160.07 | $6.51 |
| Average True Range (ATR) | 7.65 | 0.32 |
| MACD | -0.53 | 0.12 |
| Stochastic Oscillator | 72.91 | 96.67 |
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.